| Literature DB >> 33287349 |
Suji Baek1, Jisu Kim2, Byung Seok Moon3, Sun Mi Park3, Da Eun Jung3, Seo Young Kang3, Sang Ju Lee4, Seung Jun Oh4, Seung Hae Kwon5, Myung Hee Nam5, Hye Ok Kim3, Hai Jeon Yoon3, Bom Sahn Kim3, Kang Pa Lee1.
Abstract
Sarcopenia- or cachexia-related muscle atrophy is due to imbalanced energy metabolism and oxidative stress-induced muscle dysfunction. Monoterpenes play biological and pharmacological reactive oxygen species (ROS) scavenging roles. Hence, we explored the effects of camphene, a bicyclic monoterpene, on skeletal muscle atrophy in vitro and in vivo. We treated L6 myoblast cells with camphene and then examined the ROS-related oxidative stress using Mito TrackerTM Red FM and anti-8-oxoguanine antibody staining. To investigate lipid metabolism, we performed real-time polymerase chain reactions, holotomographic microscopy, and respiratory gas analysis. Rat muscle atrophy in in vivo models was observed using 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography and immunocytochemistry. Camphene reversed the aberrant cell size and muscle morphology of L6 myoblasts under starvation and in in vivo models. Camphene also attenuated E3 ubiquitin ligase muscle RING-finger protein-1, mitochondrial fission, and 8-oxoguanine nuclear expression in starved myotubes and hydrogen peroxide (H2O2)-treated cells. Moreover, camphene significantly regulated lipid metabolism in H2O2-treated cells and in vivo models. These findings suggest that camphene may potentially affect skeletal muscle atrophy by regulating oxidative stress and lipid metabolism.Entities:
Keywords: camphene; lipid metabolism; muscle atrophy; oxidative stress; sarcopenia
Mesh:
Substances:
Year: 2020 PMID: 33287349 PMCID: PMC7761825 DOI: 10.3390/nu12123731
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717